Merck (NYSE:MRK) has discontinued the vibostolimab and pembrolizumab coformulation arm of a late-stage skin cancer trial. KeyVibe-010, a randomized Phase 3 trial, was testing the investigational ...

The first abstract accepted for poster presentation contains ... investigational IO102-IO103 in combination with pembrolizumab (KEYTRUDA ®), Merck’s anti-PD-1 therapy (IOB-022/KN-D38).

Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer after surgery with curative intent, according to a study published online Oct. 16 in ...

A subgroup analysis found that pembrolizumab plus chemotherapy improved disease-free survival in high-risk patients with ...